深圳市164例非小细胞肺癌EGFR突变分析

详细信息    查看全文 | 推荐本文 |

英文篇名：Analysis of EGFR Mutations in 164 Cases of Non-Small Cell Lung Cancer in Shenzhen Area 作者：洪永忠 ; 陈延伟 ; 艾文 ; 巫翠华 ; 梁巧媚 ; 金虹 ; 廉婕 ; 徐彦飞 ; 聂莉 ; 李一禄 ; 王加顿 ; 朱巧珍 英文作者：HONG Yongzhong;CHEN Yanwei;AI Wen;WU Cuihua;LIANG Qiaomei;JIN Hong;LIAN Jie;XU Yanfei;NIE Li;LI Yilu;WANG Jiadun;ZHU Qiaozhen;Dept.of Respiratory Medicine,Nanshan People's Hospital of Shenzhen;Dept.of Respiratory Medicine,Nanshan Hospital of Shenzhen University;Nanshan People's Hospital of Shenzhen; 关键词：非小细胞肺癌 ; 表皮生长因子受体 ; 基因突变 英文关键词：Non-Small Cell Lung Cancer;;EGFR;;Gene Mutation 中文刊名：HBYK 英文刊名：Medical Journal of Wuhan University 机构：深圳市南山区人民医院呼吸科;深圳大学附属南山医院呼吸科;深圳市南山区人民医院; 出版日期：2018-06-07 09:07 出版单位：武汉大学学报(医学版) 年：2018 期：v.39 基金：广东省自然科学基金资助项目(编号:2014A031313718);; 深圳市科创委资助项目(编号:JCYJ20150402152130166) 语种：中文; 页：HBYK201805006 页数：4 CN：05 ISSN：42-1677/R 分类号：29-31+41

摘要

目的:探讨深圳市164例非小细胞肺癌患者组织样本中表皮生长因子受体(EGFR)基因的突变情况。方法:采用华因康Pstar-ⅡA基因测序仪,基于边连接边测序的DNA测序技术分析肺癌患者中EGFR基因突变的情况。结果:在164例非小细胞肺癌患者中检测到64例发生EGFR基因突变,总突变率为39.02%。其中,第18、19、20、21号外显子突变率分别3.13%(2/64),39.06%(25/64),9.38%(6/64),48.44%(31/64)。其中,19号外显子的突变以第746-750密码子的碱基缺失为主,21号外显子突变类型以L858R为主。女性肺癌患者EGFR基因的突变率显著高于男性,不吸烟者显著高于吸烟者,腺癌患者显著高于非腺癌患者(P<0.05)。结论:深圳市非小细胞肺癌EGFR基因突变以19、21号外显子为主,常见于女性、不吸烟的肺腺癌患者。
        Objective:To investigate the mutation of the EGFR gene in tissue samples from 164 patients with non-small cell lung cancer in Shenzhen.Methods:The EGFR gene in patients with lung cancer was sequenced by using HYK Pstar-Ⅱ A gene sequencing,the mutation of EGFR gene was analyzed.Results:In this study,EGFR gene mutation was detected in 64 cases of non-small cell lung cancer patients,the total mutation rates was 39.02%.Exon 18,19,20 and 21 mutation rate were 3.13%(2/64),39.06%(25/64),9.83%(6/64),48.44%(31/64),respectively.746 th-750 th codon deletion was the main mutation of exon 19,and L858 Rwas the main mutation of exon 21.The mutation rate of the EGFR gene in the female was significantly higher than that in the male,and that in non-smokers was significantly higher than that in smokers.The mutationrate of the EGFR gene in adenocarcinoma patients was considerably higher than that in non adenocarcinoma patients(P<0.05).Conclusion:EGFR gene mutations mainly occur in exon 21 and19 in non-small cell lung cancer in Shenzhen area.It is common in women and/or non-smoking adenocarcinoma patients.

引文

[1]Zhou C.Lung cancer molecular epidemiology in China:recent trends[J].Transl Lung Cancer Res,2014,3(5):270-279.
    [2]Soria JC,Ohe Y,Vansteenkiste J,et al.Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer[J].N Engl J Med,2018,378(2):113-125.
    [1]Zhang X,Zhang Y,Tang H,et al.EGFR gene copy number as a predictive/biomarker for patients with non-small-cell lung cancer receiving tyrosine kinase inhibitor treatment:a systematic review and meta-analysis[J].J Investig Med,2017,65(1):72-81.
    [4]Tu HY,Ke EE,Yang JJ,et al.A comprehensive review of uncommon EGFR mutations in patients with non-small cell lung cancer[J].Lung Cancer,2017,114:96-102.
    [5]Krawczyk P,Kowalski DM,Ramlau R,et al.Comparison of the effectiveness of erlotinib,gefitinib,and afatinib for treatment of non-small cell lung cancer in patients with common and rare EGFR gene mutations[J].Oncol Lett,2017,13(6):4 433-4 444.
    [6]Zheng Z,Jin X,Lin B,et al.Efficacy of second-line tyrosine kinase inhibitors in the treatment of metastatic advanced non-small-cell lung cancer harboring exon 19and 21EGFR mutations[J].J Cancer,2017,8(4):597-605.
    [7]Sequist LV,Bell DW,Lynch TJ,et al.Molecular predictors of response to epidermal growth factor receptor antagonists in non-small-cell lung cancer[J].J Clin Oncol,2007,25(5):587-595.
    [8]韦静妮,程雄飞,周福祥,等.150例老年非小细胞肺癌临床特点与预后因素分析[J].武汉大学学报:医学版,2013,34(3):372-376.Wei JN,Cheng XF,Zhou FX,et al.150cases of elderly non-small cell lung cancer clinical features and prognostic factors[J].Medical Journal of Wuhan University,2013,34(3):372-376.
    [9]凌云,邱田,李卓,等.非小细胞肺癌中EGFR和KRAS基因突变的特点及与临床病理特征的关系[J].临床与实验病理学杂志,2015,31(5):536-541.Ling Y,Qiu Ti,Li Z,et al.Characteristics of EGFR and KRAS mutations in non-small cell lung cancer and their relationship with clinicopathological features[J].Chinese Journal of Clinical and Experimental Pathology,2015,31(5):536-541.
    [10]张旭东,董昱,米坤,等.重组人血管内皮抑制素联合TP方案治疗晚期非小细胞肺癌的疗效及安全性的Meta分析[J].武汉大学学报:医学版,2014,35(4):645-650.Zhang XD,Dong Y,Mi K,et al.Meta-analysis of the efficacy and safety of recombinant human endostatin combined with TP regimen in the treatment of advanced non-small cell lung cancer[J].Medical Journal Wuhan University,2014,35(4):645-650.